Greg Brophy

Greg Brophy is an executive and serial entrepreneur with decades of experience in the biomedical and healthcare sectors. As the CEO of NKore Biotherapeutics LLC, Greg leads the charge in advancing cellular-based biotherapeutics for the diagnosis and treatment of cancer. Since 2021, he has overseen NKore's innovative efforts, including developing a robust diagnostic platform to measure cellular function, solidifying the company’s position at the forefront of cancer immunotherapy.

A proven track record in corporate finance, mergers and acquisitions, and the commercialization of groundbreaking medical products distinguishes Greg’s career. Before joining NKore, Greg served as the CEO of Alafair Biosciences, where he guided the commercialization of patented hydrogel technology for medical applications. At BioDlogics, he served as President and CEO, leading the company to a successful acquisition in 2016 by a public entity, thanks to its advancements in regenerative medicine.

Greg’s leadership also includes pivotal roles at HealthSouth Corporation, where he spearheaded the sale of the diagnostic division to private equity, and at CTI Molecular Imaging, where he managed the business group's successful acquisition by Siemens. His ability to lead both dynamic, high-growth environments and complex corporate turnarounds is a hallmark of his career.

Greg holds an MBA from the prestigious MIT Sloan School of Management and earned his Juris Doctor from the University of Georgia School of Law. His academic background complements his executive expertise, enabling him to navigate the intricate intersections of science, business, and law.

Known for his strategic vision and hands-on leadership, Greg remains committed to innovation and patient-focused solutions in healthcare. Under his stewardship, NKore Biotherapeutics continues to pioneer cutting-edge therapies, driving progress in the fight against cancer.